Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis

Experimental Parasitology

Volumn 127, Issue 3, 2011, Pages 658-664

  Kückelhaus, Carlos S ^a   Kückelhaus, Selma AS ^a   Muniz Junqueira, Maria Imaculada ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Leishmania (L.) amazonensis; Leishmaniasis; Pravastatin

Indexed keywords

PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOOT PAD; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN DEFECT; SKIN LEISHMANIASIS; SURVIVAL RATE; SYRIAN HAMSTER; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPROTOZOAL AGENTS; BODY WEIGHT; CRICETINAE; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MALE; MESOCRICETUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PRAVASTATIN; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

ANIMALIA; CRICETINAE; LEISHMANIA AMAZONENSIS; MESOCRICETUS AURATUS; MURINAE; MUS;

EID: 79951725721     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2010.12.003     Document Type: Article

References (47)

1. Afonso L.C., Scott P. Immune responses associated with susceptibility of C57BL/10 Mice to Leishmania amazonensis. Infection and Immunity 1993, 61:2952-2959.
2. Awasthi A., Mathur R.K., Saha B. Immune response to Leishmania infection. The Indian Journal of Medical Research 2004, 119:238-258.
3. Bogdan C., Röllinghoff M. The immune response to Leishmania: mechanism of parasite control and evasion. International Journal for Parasitology 1998, 28:121-134.
4. Bokoch G.M. Regulation of the phagocyte respiratory burst by small GTP-binding protein. Trends in Cell Biology 1995, 5:109-113.
5. Buxbaum L.U. A detrimental role for IgG and FcgammaR in Leishmania mexicana infection. Immunologic Research 2008, 42:197-209.
6. Calabrese K.S., Da-Costa S.C. Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG antigen specific vaccine. Memórias do Instituto Oswaldo Cruz 1992, 87:49-56.
7. Castellano L.R., Correia-Filho D., Argiro L., Dessein H., Prata A., Dessein A., Rodrigues V. Th1/Th2, immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon- production. Human Immunology 2009, 70:383-390.
8. Chanock S.J., El-Benna J., Smith R.M., Babior B.M. The respiratory burst oxidase. The Journal of Biological Chemistry 1994, 269:24519-24522.
9. Chen G.Z., Foster L., Bennett J.L. Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaril-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival. Naunyn-Schmiedebergs Archives of Pharmacology 1990, 342:477-482.
10. Chow S.C. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Archivum Immunologiae et Therapiae Experimentalis 2009, 57:243-251.
11. Coppens I., Bastin P., Levade T., Courtoy P.J. Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Trypanosoma brucei. Molecular and Biochemical Parasitology 1995, 69:29-40.
12. Cuba-Cuba C.A. Diagnostico parasitologico de la leishmaniasis tegumentaria americana. Revista Peruana de Medicina Experimental y Salud Publica 2000, 17:39-52.
13. Da-Cruz A., Oliveira M.P., De Luca P.M., Mendonça S.C.F., Coutinho S.G. Tumor necrosis factor-α in human American tegumentary leishmaniasis. Memórias do Instituto Oswaldo Cruz 1996, 91:225-229.
14. Dias-Zagoya J.C., Asenjo-Barrón J.C., Cárdenas-Vasquez R., Martinez E., Juárez-Oropeza M.A. Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet. Life Sciences 1999, 65:947-956.
15. Dietze R., Araújo R.C., Lima M.L.R., Vexenat J.A., Marsden P.D., Barretto A.C. Ensaio terapêutico com glucantime em sagüis (Callithrix jacchus) infectados com uma cepa de Leishmania donovani aparentemente resistente ao tratamento. Revista da Sociedade Brasileira de Medicina Tropical 1985, 18:39-42.
16. Florin-Christensen M., Florin-Christensen J., Garin C., Isola E., Brenner R.R., Rasmussen L. Inhibition of Trypanosoma cruzi growth and sterol biosynthesis by lovastatin. Biochemical and Biophysical Research Communications 1990, 166:1441-1445.
17. Franzoni F., Quiñones-Galvan A., Regoli F., Ferrannini E., Galetta F. A comparative study of the in vitro antioxidant activity of statins. International Journal of Cardiology 2003, 90:317-321.
18. Green S.J., Nacy C.A., Meltzer M.S. Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. Journal of Leukocyte Biology 1991, 50:93-103.
19. Griendling K.K., Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. The Journal of Laboratory and Clinical Medicine 1998, 132:9-15.
20. Grip O., Janciauskiene S., Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. European Journal of Pharmacology 2000, 410:83-92.
21. Ji J., Sun J., Soong L. Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis. Infection and Immunity 2003, 71:4278-4288.
22. + regulatory T cells restrain pathogenic responses during Leishmania amazonensis infection. The Journal of Immunology 2005, 174:7147-7153.
23. Jones D.E., Buxbaum L.U., Scott P. IL-4 independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. The Journal of Immunology 2000, 165:364-372.
24. Jones D.E., Ackermann M.R., Wille U., Hunter C.A., Scott P. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infection and Immunity 2002, 70:2151-2158.
25. Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. Journal of the American College of Cardiology 1999, 33:234-241.
26. Kaneta S., Satoh K., Kano S., Kanda M., Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003, 170:237-243.
27. Kuipers H.F., Biesta P.J., Groothuis T.A., Neefjes J.J., Mommaas A.M., van-den-Elsen P.J. Statins affect cell-surface expression of major histocompatibility complex Class II molecules by disrupting cholesterol-containing microdomains. Human Immunology 2005, 66:653-665.
28. Liao J.K. Beyond lipid lowering: the role of statins in vascular protection. International Journal of Cardiology 2002, 86:5-18.
29. Lobato C.M.S.D., Tavares M.L.B., Silva A.R.S., Pinto N.T. Efeito da pravastatina no comportamento de ratos submetidos à ação da nicotina. Revista Paraense de Medicina 2002, 16:23-27.
30. Maioli T.U., Takane E., Arantes R.M.E., Fietto J.L.R., Afonso L.C.C. Immune response induced by New World Leishmania species in C57BL/6 mice. Parasitology Research 2004, 94:207-212.
31. Mauël J., Ransijn A., Buchmüller-Rouiller Y. Killing of Leishmania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives. Journal of Leukocyte Biology 1991, 49:73-82.
32. Melby P.C., Chandrasekar B., Zhao W., Coe J.E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. The Journal of Immunology 2001, 166:1912-1920.
33. Monick M.M., Powers L.S., Butler N.S., Hunninghake G.W. Inhibition of Rho family GTPases results in increased TNF-α production after lipopolysaccharide exposure. The Journal of Immunology 2003, 171:2625-2630.
34. Montero M.T., Hernández O., Suárez Y., Mantila J., Ferruelo A.J., Martínez-Botas J., Gómez-Coronado D., Lasunción M.A. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000, 153:303-313.
35. Müller I., Pedrazzini T., Farrell J.P., Louis J. T-cell responses and immunity to experimental infection with Leishmania major. Annual Review of Immunology 1989, 7:561-578.
36. Muniz-Junqueira M.I., Karnib S.R., Paula-Coelho V.N., Junqueira-Jr L.F. Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals. International Immunopharmacology 2006, 6:53-60.
37. Noben-Trauth N. Susceptibility to Leishmania major infection in the absence of IL-4. Immunology Letters 2000, 75:41-44.
38. Ribeiro-de-Jesus A., Almeida R.P., Lessa H., Bacellar O., Carvalho E.M. Cytokine profile and pathology in human leishmaniasis. Brazilian Journal of Medical and Biological Research 1998, 31:143-148.
39. Rudich S.M., Mongini P.K.A., Perez R.V., Katznelson S. HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplantation Proceedings 1998, 30:992-995.
40. Sampaio R.N.R., Marsden P.D. Tratamento da forma mucosa de leishmaniose sem resposta a glucantime, com anfotericina B liposomal. Revista da Sociedade Brasileira de Medicina Tropical 1997, 30:125-128.
41. Sartori A., Roque-Barreira M.C., Coe J., Campos-Neto A. Immune complex glomerulonephritis in experimental kala-azar II: detection and characterization of parasite antigens and antibodies eluted from kidneys of Leishmania donovani-infected hamsters. Clinical and Experimental Immunology 1991, 87:386-392.
42. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental and Clinical Pharmacology 2005, 19:117-125.
43. Vasquez R.E., Soong L. CXCL10/Gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice. Infection and Immunity 2006, 74:6769-6777.
44. Walter D.H., Dimmerler S., Zeiher A.M. Effects of statins on endothelium and endothelial progenitor cell recruitment. Seminars in Vascular Medicine 2004, 4:385-393.
45. Wanasen N., Xin L., Soong L. Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection. International Journal for Parasitology 2008, 38:417-429.
46. Wassmann S., Laufs U., Baumer A.T., Müller K., Konkol C., Sauer H., Böhm M., Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Molecular Pharmacology 2001, 59:646-654.
47. Youssef S., Stüve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.